Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
about
Selling sickness: the pharmaceutical industry and disease mongering.Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenThe aging spine: new technologies and therapeutics for the osteoporotic spineEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceFRAX and the assessment of fracture probability in men and women from the UKIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisEffect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonatesPrevention and treatment of bone fragility in cancer patientManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchCalcium intake and bone mineral density: systematic review and meta-analysisPostmenopausal syndromeTreatment of primary osteoporosis in menAn overview on the treatment of postmenopausal osteoporosisDenosumab: mechanism of action and clinical outcomesBone anabolics in osteoporosis: Actuality and perspectivesThe epidemiology and management of postmenopausal osteoporosis: a viewpoint from BrazilReview of risedronate in the treatment of osteoporosisUpdate on bazedoxifene: a novel selective estrogen receptor modulatorBreast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled TrialsRheumatology: 15. OsteoporosisAlendronate and male osteoporosisThe effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancerHovenia dulcis Thunb extract and its ingredient methyl vanillate activate Wnt/β-catenin pathway and increase bone mass in growing or ovariectomized miceImpact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatmentOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Efficacy of Osteoporosis Therapies in Diabetic Patients.Progressive Spinal Kyphosis in the Aging Population.Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative.Odanacatib for the treatment of postmenopausal osteoporosis.Treatment of postmenopausal osteoporosis with odanacatib.Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium.Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.The DXL Calscan heel densitometer: evaluation and diagnostic thresholds.Validation of a 4-item score predicting hip fracture and mortality risk among elderly women.Cost-effectiveness of preventative therapies for postmenopausal women with osteopeniaGreater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.Identification and validation of vertebral compression fractures using administrative claims data.Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?
P2860
Q22242090-B777AF70-C643-4C79-8614-96B9815D2E3AQ24242258-B66BD37F-AAC6-4A55-A775-F6CDF7A3DEF0Q24609687-C354B91A-3A68-49D8-9BD4-84A0A54B1E9EQ24612411-A7526E9C-6A25-49DE-BC39-9CA3FAB6B019Q24644708-F3EC913A-640A-4CF0-85F6-467F0E445B41Q24654123-BFF46ECE-D1AB-45E8-8D6B-62CE88FF9046Q24680238-CA4D97E1-B58E-4454-8088-74458B2F3074Q24802074-0745688F-93E9-4E5A-BACB-1F38747CB18DQ26775765-47F7D990-C938-4C8B-A618-C3011DBA463CQ26782621-90D1CC61-8498-48BB-BE00-FD114500F478Q26784337-E0BC480D-DB5B-4AAA-9BC5-5997FB525904Q26795412-DFDD794B-8F0C-4DF1-BEFA-8ABCC601B77AQ26991748-827E3E79-CBC8-4904-A852-B545C37CF8DEQ27013070-B78E828E-ED9E-4C5A-8E78-0E3BA0463CBBQ27015899-C170AF21-9DAC-4667-BB3B-37862326D747Q27691122-B65244A4-221E-43AD-9B54-8BC86FDA196BQ28080673-05249DD0-D9A7-43DE-B0A4-94BF3DC331FCQ28192294-BCFC0898-81F1-491B-A8BA-13CB7B83E934Q28258998-7D663C27-07F6-47F9-9CFE-3A58A39050D8Q28269986-0EAED0F2-CDC4-4AEB-85C1-D2B776797408Q28344803-112AC19C-6DBB-44D3-9B10-7AB2EE4145ACQ28361660-4E0FC68A-F265-4D43-A31E-DA14B009786DQ28362960-701CF05D-CA76-4A13-8E87-58CA617810AFQ28538976-1C323AF1-8372-4F7F-873E-DF5CED6329B2Q28731336-72FD734C-142D-4135-A004-271A9832F389Q30235173-A5695882-50F5-435C-853C-3A9D06EF715DQ30248776-36697AF2-AA42-492C-A02E-6444691F4E77Q30278673-E4A3F1A4-2DCE-4459-BF38-75BF393BFD68Q30616581-6F0FF4A3-E8C2-4A05-9471-82FC4C5B876FQ30683504-36323E52-6F06-453A-9329-BB1FCE94387EQ30740996-F6C8995F-9E16-45AD-82D4-2126421AAF63Q31065032-3B20A9A3-13FB-406E-BD82-B31F26A4237DQ31141287-60543882-2597-4B23-B647-CE5F7F24E379Q32045038-0EF1D806-C974-4384-B0D6-1F12C1DE75F7Q33238581-5B0ACD08-C48A-4685-91C5-743815BF6542Q33270814-ED7303CB-1BCB-4213-84AB-EA8985A09D4FQ33282322-ECDD6D84-271D-462D-AD8E-2B655F980062Q33305959-5E4854FD-19E4-4B32-BD1B-55629EF114F1Q33395609-A904EF0B-A659-4B89-9E01-785B73E1A98AQ33416959-CCB76F2A-6369-4302-A8CE-8588D3BAD729
P2860
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@ast
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@en
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@nl
type
label
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@ast
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@en
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@nl
prefLabel
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@ast
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@en
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@nl
P2093
P356
P1476
Effect of alendronate on risk ...... e Fracture Intervention Trial.
@en
P2093
A Z LaCroix
D E Thompson
S R Cummings
P304
P356
10.1001/JAMA.280.24.2077
P407
P577
1998-12-01T00:00:00Z